LUMO News and Press, Lumos Pharma Inc. From 05/08/23

Oral and Poster Presentations on OraGrowtH Trials at PES 2023 Further Support Potential for LUM-201 as First Oral Treatment for Moderate Idiopathic PGHD OraGrowtH212 Interim Data Demonstrate LUM-201 Amplifies Natural Pulsatile GH-Secretion and that IGF-1 SDS and Serum Concentrations Rem...

2023-05-03 22:37:01 ET Lumos Pharma, Inc. (LUMO) Q1 2023 Results Conference Call May 03, 2023 04:30 PM ET Company Participants Lisa Miller - Senior Director, IR Rick Hawkins - CEO & Chairman Lori Lawley - CFO & Principal Accounting Officer David Karpf...

2023-05-03 17:20:04 ET Lumos Pharma press release ( NASDAQ: LUMO ): Q1 GAAP EPS of -$0.89 beats by $0.24 . Revenue of $0.69M (+527.3% Y/Y) beats by $0.57M . For further details see: Lumos Pharma GAAP EPS of -$0.89 beats by $0.24, revenue of $0.69M beats b...

-- Patient Enrollment Completed in both Phase 2 OraGrowtH Trials -- -- Primary Outcome Data for both OraGrowtH Trials Expected 4Q 2023 -- -- Interim Data from OraGrowtH Trials Accepted for Presentation at PES 2023 – -- Conference Call Scheduled for Today at 4:30pm ET ...

Oral Presentation on Growth Response to LUM-201 Treatment from OraGrowtH210 Trial Interim Data from OraGrowtH212 Trial Highlighted in Poster Presentation AUSTIN, Texas, April 27, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a...

AUSTIN, Texas, April 19, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its first quarter 2023 financial res...

AUSTIN, Texas, March 09, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in Oppenheimer&#x...

Oral Presentation Highlighting Data on 15 Subjects from OraGrowtH212 Trial Supportive of Conclusions from Interim Data Analysis Baseline Characteristics of OraGrowtH210 Trial Subjects Highlighted in Poster Presentation AUSTIN, Texas, March 05, 2023 (GLOBE NEWSWIRE) -- Lumos Phar...

Lumos Pharma, Inc. (LUMO) Q4 2022 Earnings Conference Call March 01, 2023, 16:30 ET Company Participants Lisa Miller - Senior Director, IR Richard Hawkins - CEO & Chairman Lori Lawley - CFO & Principal Accounting Officer John McKew - Chief Scientific Office...

Lumos Pharma press release ( NASDAQ: LUMO ): FY GAAP EPS of -$3.71 misses by $0.07 . Revenue of $1.52M (+560.9% Y/Y) beats by $0.38M . Lumos Pharma ended the year on December 31, 2022, with cash, cash equivalents, and short-term investments totaling $67.4 mil...